NitinJainMD

Oncology • Houston, TX

Hematologic Oncology

Physician

Join to view full profile

Dr. Jain is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jain's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2009 - 2012
Medical College of Wisconsin Affiliated HospitalsResidency, Internal Medicine, 2004 - 2007
All India Institute of Medical SciencesClass of 2003

Certifications & Licensure

FL State Medical License 2021 - Present
MI State Medical License 2023 - 2026
TX State Medical License 2012 - 2025
OK State Medical License 2020 - 2021
IL State Medical License 2009 - 2014
WI State Medical License 2005 - 2011
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2013 Oct 01
Terminated
Phase 2
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2016 Mar 18
Active, not recruiting
Phase 2
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2016 Mar 01
Terminated
Phase 1
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome Start of enrollment: 2017 Jan 31
Recruiting
Phase 2
Roles: Contact, Principal Investigator
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia Start of enrollment: 2018 Aug 24
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL Start of enrollment: 2017 Oct 30
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation Start of enrollment: 2022 Jul 14
Active, not recruiting
Phase 1
Roles: Principal Investigator, Contact
A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome Start of enrollment: 2017 Mar 08
Recruiting
Phase 2
Roles: Contact
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) Start of enrollment: 2022 Dec 20
Recruiting
Phase 2
Roles: Contact, Principal Investigator
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma Start of enrollment: 2023 Aug 01
Recruiting
Phase 1
Roles: Contact, Principal Investigator
A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Start of enrollment: 2023 Jul 05
Withdrawn
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

3 citations
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL.
Hagop Kantarjian, Nicholas J Short, Fadi G Haddad, Nitin Jain, Xuelin Huang
Journal of Clinical Oncology. 2024-12-20
1 citations
A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission.
Zaid Abdel Rahman, Tamer Othman, Rima M Saliba, Yenny Alejandra Moreno Vanegas, Razan Mohty
Transplantation and Cellular Therapy. 2024-12-01
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia...
Farhad Ravandi, Jayastu Senapati, Nitin Jain, Nicholas J Short, Tapan Kadia
Leukemia. 2024-12-01

Journal Articles

Entropic Contribution to Enhanced Thermal Stability in the Thermostable P450 CYP119
Nitin Jain, MD, Proceedings of the National Academy of Sciences
High-Grade B-cell Lymphomas with TdT Expression: A Diagnostic and Classification Dilemma
Chi Young Ok, L Jeffrey Medeiros, Sergej Konoplev, Nitin Jain, Elias Jabbour, Guilin Tang, Nature
Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes
Koichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes
Koichi Takahashi, Nitin Jain, Courtney D. DiNardo, Steven Kornblau, Carlos Bueso-Ramos, Marina Konopleva, Hagop Kantarjian, Nature
A Pilot Study of Lower Doses of Ibrutinib in Patients with Chronic Lymphocytic Leukemia
Nitin Jain, Michael J Keating, Varsha Gandhi, William G Wierda, Blood
Join now to see all

Abstracts/Posters

T Cell Determinants of Response and Resistance to PD-1 Blockade in RichterÍs Transformation
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pt...
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics ...
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphob...
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphob...
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA ...
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
Nitin Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
The Future of Chronic Lymphocytic Leukemia (CLL) Therapy
60th American Society of Hematology Annual Meeting - 12/3/2018
The Future of Chronic Lymphocytic Leukemia (CLL) Therapy
60th American Society of Hematology Annual Meeting - 12/1/2018

Press Mentions

ASH: Triplet Combination Regimens Demonstrate High Response Rates in Multiple LeukemiasDecember 10th, 2024
New Directions in ALL, CML, and CLL TreatmentOctober 14th, 2024
$Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL$
Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLLJune 17th, 2024
Join now to see all